Navigation Links
PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants
Date:7/31/2009

ANNAPOLIS, Md., July 31 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced that, effective July 28, 2009, it has closed on the issuance of 2-year, 10% unsecured senior convertible notes ("Notes") and common stock purchase warrants ("Warrants") in a private placement of approximately $19.3 million.

In connection with the private placement, the Company has received gross cash proceeds of approximately $10.5 million from new investors, including an aggregate of approximately $8.5 million from unaffiliated investors, and has exchanged approximately $8.8 million in outstanding principal and unpaid accrued interest under the Company's 8% senior unsecured convertible notes originally issued in August 3, 2007 and due August 3, 2009 (the "Old Notes").

Cash proceeds from the sale of the Notes and Warrants will be used (i) to repay approximately $5.7 million in principal and unpaid accrued interest due to holders of the Old Notes that have not elected to participate in this financing transaction, (ii) to repay all remaining amounts (approximately $2.7 million), including certain prepayment fees, due and owing under the Company's outstanding secured credit facility, and (iii) for other working capital purposes. The Company estimates that at its currently projected rate of net cash consumption, the net proceeds from this financing along with existing sources of cash will be sufficient to fund operations through the end of 2010.

Interest on the Notes will accrue at a rate of ten percent (10%) per year. The Notes are convertible by the holders thereof at any time into shares of PharmAthene's common stock at a conversion price of $2.541667/share, which represents the closin
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
3. Genmab Discloses Target and Development Plans for HuMax-Inflam
4. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
5. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
6. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. BioVex Closes Second Round of Series E Financing
9. Pharmaxis Closes Share Purchase Plan
10. The closest look ever at native human tissue
11. Helix BioPharma closes $16.9 million private placement of common shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading regenerative ... study of its canine osteoarthritis stem cell product, currently under development for FDA ... and will be marketed in the US by Aratana. This product, termed AT-016, ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... advanced fluid applications and designed for continuous operation up to 1500 bar. The ... ensuring safety, efficiency, and preventing toxic contamination. , The Pony™ NS2006L homogenizer is ...
(Date:7/29/2015)... 29, 2015 US-Australian drug discovery company, Novogen ... it is committed to progressing its ground-breaking technology platforms ... and to ensure the Company delivers the best value ... Iain Ross , said the Company currently had an ... programs, discovery programs and academic partnerships and initiatives, and ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 2Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 3Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 4Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 5Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 6Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 7Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 8Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 9Newly Appointed Acting CEO Outlines Immediate Plans for Novogen 10
... BrainPort technology will be discussed at a Monday, Oct. ... president and chief executive officer at Wicab , ... an overview of the business plan and the planned ... BrainPort balance device in the United States and Europe ...
... from company offices and using broadband services to help them ... by a Milwaukee company for ITAC , the Telework ... ,"The ability for people to work from anywhere is attributed ... communication technologies," said Robert L. Smith of ITAC, in Silver ...
... announced that Dick Blick ... Warehouse and RedPrairie DLx Labor at its distribution center in ... Highland Park, Ill., offers more than 30,000 art supply products ... , Analytical Surveys, Inc., ...
Cached Biology Technology:More Americans working away from the office 2
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
(Date:7/23/2015)... 23, 2015 Research and Markets ( ... "Global Outlook of the Biometrics Industry 2015 ... The global biometrics market is likely to ... applications owing to the uptake of multiple technologies ... that enhances the growth of biometrics in existing ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... 22Nearly 6,000 researchers from around the world will present ... of light waves at the 2008 Conference on Lasers ... May 4-9 at the San Jose McEnery Convention Center ... preeminent event for those in the lasers and electro-optics ...
... origins of life and culminating with the latest findings ... will report on research spanning three billion years of ... symposium takes place on Thursday, May 1, and Friday, ... is free and open to the public. The ...
... Sharks in captivity avoid metals that react with seawater ... help fishery biologists develop a strategy to reduce the ... is an increasing priority worldwide given diminished populations of ... species for baited lines, reducing fishing efficiency and increasing ...
Cached Biology News:Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 2Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 3Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 4Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 5Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 6Detecting dangerous chemicals with lasers, exploring the brain's circuitry with light and more 7Rockefeller University hosts 2-day evolution symposium, May 1-2, 2008 2Can certain metals repel sharks from fishing gear? 2Can certain metals repel sharks from fishing gear? 3
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide....
... The Luminex 100 Instrument System is ... assays using Upstate's Beadlyte reagents. The ... Dell computer with software version 1.7, ... Delivery System. Upstate offers $2000 in ...
normal human fibroblasts Source: Cell Lysate Form: Ready to Use Application: Western Blotting Control...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: